CURRICULUM VITAE
PERSONAL INFORMATION
Name: Jonathan Chernoff, M.D., Ph.D.
Address: Fox Chase Cancer Center
333 Cottman Avenue, W455
Philadelphia, PA 19111
Phone: (215) 728-5319
Fax: (215) 728-3616
Email: Jonathan.Chernoff@fccc.edu
Lab website: https://www.foxchase.org/jonathan-chernoff
EDUCATION
1984 - M.D, Ph.D. Mount Sinai School of Medicine (Medical Scientist Training Program (Discipline: Biochemistry)
1978 - B.A. Yale College (Discipline: Molecular Biophysics & Biochemistry)
PROFESSIONAL EXPERIENCE
2021 - present Cancer Center Director, Senior Vice President, Fox Chase Cancer Center; Senior Associate Dean for Cancer Research Programs, Lewis Katz School of Medicine at Temple University
2010 - 2021 Scientific Director, Senior Vice President, Deputy Cancer Center Director, Fox Chase Cancer Center
2008 - 2010 Vice President, Deputy Scientific Director, Fox Chase Cancer Center
2008 - present Stanley P. Reimann Chair in Oncology Research, Fox Chase Cancer Center
2004 - present Adjunct Professor, Drexel University School of Medicine
2002 - present Professor (senior member), Fox Chase Cancer Center
1999 - present Co-Director, Cancer Biology Program, Fox Chase Cancer Center
1996 - present Adjunct Assistant Professor, University of Pennsylvania
1996 - 2002 Associate Professor (member w/tenure), Fox Chase Cancer Center
1991 - 1996 Assistant Professor (associate member), Fox Chase Cancer Center
1988 - 1991 Postdoctoral Fellow (Erikson lab), Department of Cellular & Developmental Biology, Harvard University
1988 - 1990 Clinical Fellow, Hematology/Oncology Department, Beth Israel Hospital
1987 - 1988 Clinical Fellow, Department of Medical Oncology, The Johns Hopkins Oncology Center
1984 - 1987 Resident, Department of Internal Medicine, University Health Center of Pittsburgh
HONORS AND AWARDS
2023 Associate Fellow, Branford College, Yale University
2021 - present FWO Review College (Belgium)
2019 - 2021 Selection Committee, AACR Outstanding Investigator Award in Breast Cancer Research
2018 Co-Chair, AACR Annual Meeting Program Committee
2017 Fellow, American Association for the Advancement of Science (AAAS)
2017 Chairperson AACR Gertrude B. Elion Cancer Research Grant Scientific Review Committee
2016 Co-Organizer, Celebrating AKT Symposium
2016 Senior Faculty Award, 4th Annual Temple Translational Science Symposium
2016 - 2022 Member, Interurban Clinical Club
2014 AACR, Educational Session Leader
2013 Pennsylvania Drug Discovery Institute, Drug Discovery Award
2011 - 2012 Chair: NF2 Preclinical Consortium
2010 ACS Scientific Research Award, Southeast PA Region
2010 Russian Academy of Science, Conference on Gene Expression, session leader
2010 NF Conference, session leader
2008 - 2011 Senior Fellow, American Asthma Association
2008 - present Member, The Kinome Virtual Academy of the Targeted Proteins Database
2007 Dozer Lecturer, Ben Gurion University
2005 - present Member, Faculty of 1000
2007 Chair, Gordon Conference “Mechanisms of Cell Signaling”
2006 Vice Chair, FASEB “Small G Protein Networks in Cell Dynamics”
2005 Vice Chair, Gordon Conference “Mechanisms of Cell Signaling”
1997 - 2002 Leukemia Society of America (Scholar)
1993 - 1998 American Cancer Society Research Scholar
1993 - 1996 W.W. Smith Charitable Trust Fellowship
1996 Pfizer Traveling Fellow Award
CERTIFICATIONS AND LICENSURE
American Board of Internal Medicine
Subspecialty Board – Medical Oncology
Medical License – Pennsylvania
PATENTS
U.S. Patent 11,240,996 B2 “Mice with transgene of iBox peptide inhibitor of Group B p21-activated kinases”
BIBLIOGRAPHY
(~282, H index = 65 (Web of Science); = 81 (Google Scholar)) https://scholar.google.com/citations?hl=en&user=mI7OViIAAAAJ
REFEREED JOURNALS
1. Chernoff, J., Li, H.C., Cheng, Y.S.E. and Chen, L.B. Characterization of a phosphotyrosyl protein phosphatase activity associated with a phosphoseryl protein phosphatase of Mr = 95,000 from bovine heart. J. Biol. Chem. 258:7852, 1983.
2. Chernoff, J. and Li, H.C. Multiple forms of phosphotyrosyl- and phosphoseryl-protein phosphatase from cardiac muscle: partial purification and characterization of an EDTA stimulated phosphotyrosyl-protein phosphatase. Arch. Biochem. Biophys. 226:517, 1983.
3. Li, H.C., Chernoff, J., Chen, L.B. and Kirschonbaum, A. A phosphotyrosyl protein phosphatase activity associated with acid phosphatase from human prostate gland. Eur. J. Biochem. 138:45, 1984.
4. Chernoff, J., Sells, M.A. and Li, H.C. Characterization of phosphotyrosyl protein phosphatase activity associated with calcineurin. Biochem. Biophys. Res. Comm. 121:141, 1984.
5. Sells, M.A., Chernoff, J., Cerda, A., Bowers, C., Shafritz, D.A., Kase, N., Christman, J.K.
and Acs, G. Long-term culture and passage of human fetal liver cells that synthesize albumin. In Vitro Cell. Dev. Biol. 21:216, 1985.
6. Chernoff, J. and Li, H.C. A major phosphotyrosyl-protein phosphatase from bovine heart is associated with a low-molecular-weight acid phosphatase. Arch. Biochem. Biophys. 240:135, 1985.
7. Chernoff, J., Schievella, A.G., Jost, C.J., Erikson, R.L. and Neel, B.G. Cloning of the cDNA of a major human protein-tyrosine-phosphatase. Proc. Natl. Acad. Sci. USA 87:2735-2739, 1990.
8. Ottilie, S., Chernoff, J., Hannig, G., Hoffman, C.S. and Erikson, R.L. A fission yeast gene encoding a protein with features of protein-tyrosine-phosphatases. Proc. Natl. Acad. Sci. USA 88: 3455-3459, 1991.
9. Ottilie, S., Chernoff, J., Hannig, G., Hoffman, C.S. and Erikson, R.L. The fission yeast genes pyp1 and pyp2 encode protein tyrosine phosphatases that negatively regulate mitosis. Mol. Cell. Biol. 12:5571-5580, 1992.
10. Patriotis, C., Makris, A., Chernoff, J., and Tsichlis, P.N. Tpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase. Proc. Natl. Acad. Sci. USA 91:9755, 1994.
11. Sells, M.A. and Chernoff, J. Epitope-tagging vectors for eukaryotic protein production. Gene 152:187-189, 1995.
12. Sells, M.A, Li, J. and Chernoff, J. Delivery of protein into cells using polycationic liposomes. BioTechniques 19:72-78, 1995.
13. Knaus, U.G., Morris, S., Dong, H.-J., Chernoff, J., and Bokoch, G.M. Regulation of p21activated kinases through G protein-coupled receptors. Science 269:221-223, 1995.
14. Creasy, C.L. and Chernoff, J. Cloning and characterization of a human protein kinase with homology to Ste20. J. Biol. Chem. 270:21695-21700, 1995.
15. Bagrodia, S., Taylor, S., Creasy, C.L., Chernoff, J., and Cerione, R.A. Identification of a murine p21Cdc42/Rac activated kinase (PAK). J. Biol. Chem. 270:22731-22738, 1995.
16. Zhang, S., Han, J., Sells, M.A., Chernoff, J., Knaus, U.G., Ulevitch, R.J., and Bokoch, G.M. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J. Biol. Chem. 270: 23934-23936, 1995.
17. Vambutas, V., Kaplan, D.R., Sells, M.A., and Chernoff, J. NGF stimulates tyrosine phosphorylation and activation of SH-PTP1 in PC12 cells. J. Biol. Chem. 270: 2562925634, 1995.
18. Creasy, C.L. and Chernoff, J. Cloning and characterization of a member of the MST subfamily of Ste20-like kinases. Gene 167: 303-306, 1995.
19. Ottilie, S., Miller, P.J., Johnson, D.I., Creasy, C.L., Sells, M.A., Bagrodia, S., Forsburg,
S.L., and Chernoff, J. Fission yeast pak1+ encodes a protein kinase that interacts with Cdc42p and is involved in the control of cell polarity and mating. EMBO J. 14:5908-5919, 1995.
20. Creasy, C.L., Ambrose, D.M., and Chernoff, J. The human Ste20-like kinase, Mst1, dimerizes and contains an inhibitory domain. J. Biol. Chem. 271:21049-21053, 1996.
21. Galisteo, M.L., Chernoff, J., Su, Y.-C., Skolnik, E.Y., and Schlessinger, J. The adaptor protein Nck links receptor tyrosine kinases with the serine/threonine kinase Pak1. J. Biol. Chem. 271:20997-21000, 1996.
22. Liu, F., Hill, D.E., and Chernoff, J. Direct binding of the proline rich region of Protein Tyrosine Phosphatase 1B to the Src homology 3 domain of p130Cas. J. Biol. Chem. 271:31290-31295, 1996.
23. Bandyopadhyay, D., Kusari, A., Kenner, K., Liu, F., Chernoff, J., Gustafson, T.A., and Kusari, J. Protein Tyrosine Phosphatase 1B binds to the insulin receptor in vivo and is tyrosine phosphorylated in the presence of insulin. J. Biol. Chem. 272:1639-1645, 1997.
24. Sells, M.A., Knaus, U.G., Bagrodia, S., Ambrose, D., Bokoch, G.M. and Chernoff, J.
Human p21-activated kinases (Paks) regulate actin reorganization in mammalian cells. Curr. Biol. 7:202-210, 1997.
25. Tang, Y., Chen, Z., Ambrose, D., Liu, J., Gibbs, J.B., Chernoff, J., and Field, J. Kinase deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol. Cell. Biol. 17:4454-4464, 1997.
26. Liu, F. and Chernoff, J. Protein tyrosine phosphatase 1B interacts with epidermal growth factor receptor in cultured cells. Biochem. J. 327:139-145, 1997.
27. Liu, F., Sells, M.A., and Chernoff, J. Suppression of oncogene-mediated transformation of rat 3Y1 fibroblasts by protein tyrosine phosphatase 1B requires a functional SH3-ligand. Mol. Cell. Biol. 18:250-259, 1998.
28. Liu, F., Sells, M.A., and Chernoff, J. Protein tyrosine phosphatase 1B negatively regulates integrin signaling. Curr. Biol. 8:173-176, 1998.
29. Zhang, B., Chernoff, J., and Zheng, Y. Interaction of Rac1 with GTPases-activating proteins and putative effectors. J. Biol. Chem. 273:8776-8782, 1998.
30. Graves, J.D., Gotoh, Y., Draves, K.E. Ambrose, D., Han, D.K.N., Wright, M., Chernoff, J., Clark, E.A., Krebs, E.G. Caspase-mediated cleavage and activation of the mammalian Ste20-like kinase Mst1 during apoptosis. EMBO J. 17:2224-2234, 1998.
31. Sells, M.A., Barratt, J.T., Caviston, J., Ottilie, S., Leberer, E., and Chernoff, J.
Characterization of Pak2, a pleckstrin-homology-domain-containing p21-activated protein kinase from fission yeast. J. Biol. Chem. 273:18490-18498, 1998.
32. Adam, L., Vadlamudi, R., Kondapaka, S.B., Chernoff, J., Mendelsohn, J., and Kumar, R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J. Biol. Chem. 273:28238-28246, 1998.
33. Wardenburg, J.B., Pappu, R., Bu, J.-Y., Mayer, B., Chernoff, J., Straus, D., and Chan, A.C. Regulation of PAK activation and the T cell cytoskeleton by the linker protein SLP-76 Immunity, 9: 607-616, 1998.
34. Sells, M.A., Boyd, J., and Chernoff, J. p21-activated kinase regulates motility in mammalian fibroblasts. J. Cell Biol. 145:837-849, 1999. (cover story)
35. Adam L, Vadlamudi RK, Mandal M, Chernoff J, and Kumar R. p21-activated kinase-1 regulates microfilament reorganization and invasiveness of breast cancer cells. J. Biol. Chem, 275:12041-12050, 2000.
36. Dadke, S, Kusari, J, and Chernoff, J. Down-regulation of insulin signaling by Protein Tyrosine Phosphatase (PTP) 1B is mediated by an N-terminal binding region. J. Biol. Chem. 275:23642-23647, 2000.
37. Dharmawardhane, S., Schurmann, A., Sells, M.A., Chernoff, J., Schmid, S.L., and Bokoch, G.M. Regulation of macropinocytosis by p21-activated kinase-1. Mol. Biol. Cell 11:33413352, 2000.
38. Vadlamudi, R.K., Ratna K., Adam, L., Wang, R.-A., Mandal, M., Nguyen, D., Sahin, A., Chernoff, J., Hung, M.-C., and Kumar, R. Regulatable expression of p21-activated kinase1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J. Biol. Chem. 275:36238-36244, 2000.
39. Arora, V.K., Molina, R.P., Foster, J.L., Blakemore, J.L., Chernoff, J., Fredericksen, B.L., and Garcia, J.V. Lentiviral Nef specifically activates Pak2. J. Virol. 74:11081-11087, 2000.
40. Sells, M.A., Pfaff, A., and Chernoff, J. Temporal and spatial distribution of activated Pak1 in fibroblasts. J. Cell Biol. 151:1449-1457, 2000.
41. Mota, M. Reeder, M.K., Chernoff, J., and Bazenet, C.E. Evidence for a role of mixedlineage kinases in neuronal apoptosis. J. Neurosci. 21:4949-4957, 2001
42. Reeder, M.K., Serebriiskii, I.G., Golemis E.A., and Chernoff, J. Analysis of small GTPase signaling pathways using Pak1 mutants that selectively couple to Cdc42. J. Biol. Chem. 276:40606-40613, 2001.
43. Dadke, S. and Chernoff, J. Interaction of Protein-Tyrosine Phosphatase (PTP)1B with its substrates is influenced by two distinct binding domains. Biochem. J. 364:377-383, 2002.
44. Thiel, D.A., Reeder, M.K., Pfaff, A., Coleman, T.R., Sells, M. A., and Chernoff, J. Cell cycle regulated phosphorylation of p21-activated kinase 1 (Pak1) Curr. Biol. 12:1227-1232, 2002. Recommended at F1000 Prime (http://f1000.com/prime/1008958).
45. Li, F., Adam, L., Vadlamudi, R.K., Zhou, H., Sen, S., Chernoff, J., Mandal, M.,and Kumar, R. p21-activated kinase 1 interacts with and phosphorylates Histone H3 in breast cancer cells. EMBO Reports 3:767-773, 2002.
46. Astrinidis, A, Cash, T.P., Hunter, D.S., Walker, C.L., Chernoff, J., and Henske. E.P. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion, and migration. Oncogene 21:8470-8476, 2002.
47. Serebriiskii, I.G., Mitina, O., Pugacheva, E., Benevolenskaya, E., Kotova, E., Toby, G.G., Khazak, V., Kaelin, W.G., Chernoff, J., and Golemis, E.A. Detection of peptides, proteins, and drugs that selectively interact with protein targets. Genome Res. 12:1785-1791, 2002.
48. Penzes, P., Beeser, A., Chernoff, J., Schiller, M.R., Eipper, B.A., Mains, R.E., and Huganir, R.L. Rapid induction of dendritic spine morphogenesis by trans-synaptic ephrinB-EphB receptor activation of the Rac1-GEF kalirin. Neuron 37:263-274, 2003. Recommended at F1000 Prime (http://f1000.com/prime/1011905)
49. Cheung, W.L., Ajiro, K., Samejima, K., Kloc, M., Cheung, P., Mizzen, C.A., Beeser, A., Etkin, L.D., Chernoff, J., Earnshaw, W.C., and Allis, C.D. Apoptosis in vertebrates is characterized by phosphorylation of histone H2B mediated by Mammalian Sterile Twenty kinase Cell, 113:507–517, 2003.
50. Deacon, K., Mistry, P., Chernoff, J., Blank, J.L., and Patel, R. p38 MAP kinase mediates cell death and p21-activated kinase (PAK) mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol. Biol. Cell 14:2071-2087, 2003.
51. Cotteret, S., Jaffer, Z.M., Beeser, A. and Chernoff, J. p21-activated kinase-5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol. Cell. Biol., 23:5526-5539, 2003.
52. Zegers, M.M.P., Forget, M.A., Chernoff, J., Mostov, K.E., ter Beest, M.B.A., and Hansen,
S.H. Pak1 and PIX regulate contact inhibition during epithelial wound healing. EMBO J.,
22:4155-4165. 2003. Recommended at F1000 Prime (http://f1000.com/prime/1014981)
53. Dadke, S. and Chernoff, J. Protein-tyrosine phosphatase 1B mediates the effects of insulin on the actin cytoskeleton in immortalized fibroblasts. J. Biol. Chem., 278:40607-40611, 2003.
54. Cai, D., Iyer, A., Near, R.I., Felekkis, K.N., Luo, Z., Albanese, C., Peste, R.G., Chernoff, J., and Lerner, A. AND-34/BCAR3, a GDP exchange factor whose over-expression confes anti-estrogen resistance, activates Rac, PAK, and the cyclin D promoter. Cancer Res., 63:6802-6808, 2003.
55. Reynolds, L.F., de Bettigniers, C., Norton, T., Beeser, A., Chernoff, J., and Tybulewicz, V.L.J. Vav1 transduces T cell receptor signals to the activation of the Ras/ERK pathway via LAT, Sos, and RasGRP1. J. Biol. Chem., 279:18239-18246, 2004.
56. Parsons, M., Monypenny, J., Ameer-Beg, S.M., Millard, T.H., Machesky, L.M., Peter, M., Keppler, M.D., Schiavo, G., Watson, R., Chernoff, J., Zicha, D., Vojnovic, B., Ng, T.
Spatially Distinct Binding of Cdc42 to PAK1 and N-WASP in Breast Carcinoma Cells. Mol. Cell. Biol., 25:1680-1695, 2005.
57. Gonzalez Guerrico, A.M., Jaffer, Z.M., Page, R.E., Braunewell, K.-H., Chernoff, J., and Klein-Szanto, A.J.P. Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration in squamous carcinoma cells. Oncogene, 24:2307-2316, 2005.
58. Leisner, T.M., Liu, M., Jaffer, Z.M., Chernoff, J., Parise, L.V. Essential role of CIB1 in regulating PAK1 activation and cell migration. J. Cell Biol., 170:465-476, 2005.
59. Beeser, A., Jaffer, Z.M., Hofmann, C., and Chernoff, J. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J. Biol. Chem., 280:36609-36615, 2005.
60. Li, S., Depetris, R., Barford, D., Chernoff, J., and Hubbard, S.R. Crystal structure of protein tyrosine phosphatase 1B bound to the insulin receptor tyrosine kinase. Structure, 13:1643-
1651, 2005. Recommended at F1000 Prime (http://f1000.com/prime/1030175)
61. Bartholomew, P.J., Jones, C.W., Benware, A., Hanks, S., Chernoff, J., and LaFlamme, S.E. Regulation of the catalytic activity of PTP1B: roles for cell adhesion, tyrosine residue 66, and proline residues 309 and 310. Exp. Cell Res., 311:294-306, 2005.
62. Cotteret, S. and Chernoff, J. Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic properties. Mol. Cell Biol., 26:3215-3230, 2006.
63. ten Klooster, J.P., Jaffer, Z.M., Chernoff, J., and Hordijk, P.L. Targeting and activation of Rac1 are mediated by the exchange factor b-Pix. J. Cell Biol., 172:759-769, 2006.
64. Pirruccello, M., Sondermann, H., Pelton, J.G., Pellicena, P., Hoelz, A., Chernoff, J., Wemmer, D.E., and Kuriyan, J. Dimeric kinase assembly underlying autophosphorylation in the p21 activated kinases. J. Mol. Biol., 361:312-326, 2006.
65. Thullberg, M., Gad, A., Beeser, A., Chernoff, J., and Strömblad, S. The kinase-inhibitory domain of p21-activated kinase 1 (PAK1) inhibits cell cycle progression independent of PAK1 kinase activity. Oncogene, 26:1820-1828, 2007.
66. Dadke, S., Cotteret, S., Yip, S.-C., Jaffer, Z.M., Haj, F., Ivanov A., Rauscher III, F., Shuai, K., Ng, T., Neel, B.G., and Chernoff, J. Regulation of Protein-Tyrosine Phosphatase (PTP) 1B by sumoylation Nat. Cell Biol. 9:80-85, 2007.
67. Rennefahrt, U.E.E., Deacon, S., Parker, S.A., Devarajan, K., Beeser, A., Chernoff, J., Knapp, S., Turk, B.E., and Peterson, J.R., Comprehensive specificity profiling of Pak kinases allows identification of novel phosphorylation sites. J. Biol. Chem. 282:1566715678, 2007.
68. Friedland, J.C., Lakins, J.N., Kazanietz, M.G., Chernoff, J., Boettiger, D., and Weaver, V.M. α6β4 integrin activates Rac-dependent p21-activated kinase 1 to drive NFêBdependent apoptosis resistance in 3D mammary acini. J. Cell Sci. 120:3700-3712, 2007.
69. Mao, K., Kobayashi, S., Jaffer, Z.M., Huang, Y., Volden, P., Chernoff, J., and Liang, Q.
Regulation of Akt/PKB activity by p21-activated kinase in cardiomyocytes. J. Mol. Cell. Cardiol. 44:429-434, 2008.
70. Deacon, S.W., Beeser, A., Fukui, J.A., Rennefahrt, U.E.E., Myers, C., Chernoff, J., and Peterson, J. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem. Biol., 15:322-331, 2008. (Deacon and Beeser, co-first authors).
71. McDaniel, A.S, Allen, J.D., Park, S.-J., Michels, E.G., Burgin, S.J., Chen, S., Bessler, W.K., Chernoff, J., and Clapp, D.W*. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-infunction phenotypes in Nf1+/- mast cells. Blood 112:4646-4654, 2008.
72. Smith S.D., Jaffer, Z.M., Chernoff, J., and Ridley, A.J. PAK1-mediated activation of ERK1/2 regulates lamellipodial dynamics. J. Cell Sci. 121:3729-3736, 2008.
73. Allen, J.D., Jaffer, Z.M., Burgin, S., Hofmann, C., Sells, M.A., Derr-Yellin, E., Michels,
E.G., Bessler, W.K., Ingram, D.A., Chernoff, J.*, and Clapp, D.W.* p21-activated kinase 1
is required in mast cells for FceRI-mediated inflammatory responses. Blood. 113:26952705, 2009. *co-corresponding authors. (Allen and Jaffer, co-first authors, Chernoff and Clapp co-senior authors).
74. Van den Broeke, C., Radu, M., Deruelle, M., Nauwynck, H., Hofmann, C., Jaffer, Z.M., Chernoff, J. and Favoreel, H.W. Alpha-herpesvirus US3-mediated reorganization of the actin cytoskeleton is mediated by p21-activated kinases 1 and 2. Proc. Natl. Acad. Sci. 106:8707-8712, 2009.
75. Arias-Romero, L.E., Saha, S., Villamar, O., Yip, S.-C., Ethier, S.P., Zhang, Z-Y., and Chernoff, J. Activation of Src by Protein Tyrosine Phosphatase (PTP)1B is required for ErbB2 transformation of breast epithelial cells. Cancer Res. 69:4582-4588, 2009.
76. Flaiz, C., Chernoff, J. Ammoun, S., Peterson, J.R., and Hanemann, C.R. PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Exp. Neurology 218:137-144, 2009.
77. Lightcap, C.M., Kari, G., Arias-Romero, L.E., Chernoff, J., Rodeck, U., and Williams, J.C. Interaction with LC8 Is required for Pak1 nuclear import and is indispensable for Zebrafish development. PLoS ONE 4:e6025, 2009.
78. Menges, C., Chen, Y., Mossman, B., Chernoff, J., Yeung, A., and Testa, J.R. A Phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in Malignant Mesothelioma. Genes & Cancer 1:493-505, 2010.
79. Arias-Romero, L., Villamar-Cruz, O., Pacheco, A., Kosoff, R., Huang, M., Muthuswamy, S., and Chernoff, J. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene 29:5839-5849, 2010.
80. Molli, P.R., Li, D.Q., Bagheri-Yarmand, R., Pakala, S.B., Katayama, H., Sen, S., Iyer, J., Chernoff, J., Tsai, M.Y., Nair, S.S., and Kumar, R. Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J. Cell Biol. 190:101-114, 2010.
81. Chow, H.-Y., Stepanova, D., Koch, J., and Chernoff, J. p21-activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. PLoS ONE 5:e13791, 2010. doi:10.1371/ journal.pone.0013791.
82. Makhlin, I., Zhang, J., Chernoff, J., and Boorjian, S. The mTOR pathway impacts proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. Brit. J. Urol. 108:E84-90, 2011.
83. Van den Broeke, C., Radu, M., Nauwynck, H.J., Chernoff, J., Favoreel, H.W. Role of group A p21-activated kinases in the anti-apoptotic activity of the pseudorabies virus US3 protein kinase. Virus Res. 155:376-380, 2011.
84. De La Mota-Peynado, A., Chernoff, J, and Beeser A. Identification of the atypical extracellular regulated kinase 3 (Erk3) as a novel substrate for p21-activated kinase (Pak) activity. J. Biol. Chem. 286:13603-13611, 2011.
85. Shepelev, M.V., Chernoff, J., and Korobko, I. Rho Family GTPase Chp/RhoV induces PC12 apoptotic cell Death via JNK activation. Small GTPases 2:17-26, 2011.
86. Delorme-Walker, V.D., Peterson, J.R., Chernoff, J., Waterman, C.M., Danuser, G., Dermardirossian, C., Bokoch, G.M. Pak1 regulates focal adhesion strength, myosin IIA distribution, and actin dynamics to optimize cell migration. J. Cell Biol. 193:1289-1303, 2011. Recommended at F1000 Prime (http://f1000.com/prime/13013958)
87. Sela, M., Bogin, Y., Beach, D., Oellerich, T., Lehne, J., Smith-Garvin, J., Okumura, M., Starosvetsky, E., Kosoff, R., Libman, E., Koretzky, G.A., Kambayashi, T., Urlaub, H., Wienands, J., Chernoff, J., and Yablonski, D. Sequential phosphorylation of SLP-76 at tyrosine 173 is required for activation of T and Mast cells. EMBO J. 30:3160-3172, 2011.
88. Li, A., Ma, Y., Mort, R.L., Lindsay, C., Stevenson, D., Strathdee, D., Insall, R.H., Chernoff, J., Snapper, S.B. Jackson, I.J., Larue, L., Sansom, O.J., and Machesky, L.M. Rac1 drives melanoblast organization during mouse development by orchestrating pseudopod-driven motility and cell cycle progression. Dev. Cell 21:722-734, 2011.
89. Wang, X., Oh, E., Clapp, D.W., Chernoff, J., and Thurmond„ D.C. Inhibition or ablation of p21-activated kinase (PAK1) disrupts glucose homeostatic mechanisms in vivo. J. Biol. Chem. 286:41359-41367, 2011.
90. Taglieri, D.M., Monasky, M.M., Knezevic, I, Sheehan, K.A., Lei, M., Wang X., Chernoff, J., Wolska, B.M., Ke, Y., and Solaro, R.J. Ablation of p21-activated kinase in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2. J. Mol. Cell Cardiol. 51:988-996, 2011.
91. Yip, S.C., Cotteret, S., and Chernoff, J. Sumoylated Protein Tyrosine Phosphatase (PTP)1B localizes to the inner nuclear membrane and regulates the tyrosine phosphorylation of emerin. J. Cell Sci. 125:310-316, 2012.
92. Monasky, M.M., Taglieri, D.M., Patel, B.G., Chernoff, J., Wolska, B.M., Ke, Y., and Solaro, R.J. p21-activated kinase improves myocardial performance during ischemia/reperfusion injury by modulation of Troponin-T and Myosin Light Chain 2 phosphorylation. Am. J. Physiol. 302:H224-230, 2012.
93. Hoover, W.C., Zhang, W., Xue, Z., Gao, H., Chernoff, J., Clapp, D.W., Gunst, S.J., and Tepper, R.S. Inhibition of p21-activated kinase (PAK) reduces airway responsiveness in vivo and in vitro in murine and human airways. PLoS One 7:e42601, 2012.
94. Jhaveri, K.A., Debnath, P., Chernoff, J., Sanders, J., and Schwartz, M.A. The role of p21activated kinase in the initiation of atherosclerosis. BMC Cardiovascular Disorders 12:5562, 2012.
95. Menges, C.W., Sementino, E., Talarchek, J., Xu, J., Chernoff, J., Peterson, J.R., and Testa, J.R. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways. Mol. Cancer Res. 10:1178-1188, 2012.
96. Chow, H.Y., Jubb, A.M., Koch, J.N., Jaffer, Z.M., Stepanova, D., Campbell, D.A., Duron, S. G., O’Farrell, M., Cai, Q., Klein-Szanto, A.J., Gutkind, J.S., Hoeflich, K.P., and Chernoff, J. p21-activated kinase 1 is required for efficient tumor formation and progression in a Rasmediated skin cancer model. Cancer Res. 72:5966-5975, 2012.
97. Chiang, Y.A., Shao, W., Chernoff, J., and Jin, T. p21-activated protein kinase 1 (Pak1) mediates the crosstalk between insulin and β-catenin on proglucagon gene expression and its ablation affects glucose homeostasis. Endocrinology 154:77-88, 2013.
98. Kosoff, R., Chow, H.Y., Radu, M., and Chernoff, J. Pak2 restrains mast cell FcεRIsignaling through modulation of Rho GEF activity. J. Biol. Chem. 288:974-983, 2013.
99. Radu, M. and Chernoff, J. An in vivo assay to test blood vessel permeability. J. Vis. Exp. 16:e50062, 2013.
100. Dorrance, A.M., De Vita, S., Radu, M., Reddy, P.N.G., McGuinness, M.K., Harris, C.E., Mathieu, R., Lane, S.W., Kosoff, R., Milsom, M.D., Chernoff, J.,* and Williams, D.A. * The Rac GTPase effector p21 Activated Kinase-2 is essential for hematopoietic stem/progenitor cell migration and engraftment. Blood 121:2474-82, 2013 *(co-senior authors)
101. Huynh, N., Yim, M., Chernoff, J., Shulkes, A., Baldwin, G.S., and He, H. p21-activated kinase 1 mediates gastrin-stimulated proliferation of the colorectal mucosa via multiple signalling pathways. Am J Physiol. Gastrointest. Liver Physiol. 304:G561-7, 2013.
102. Rawat, S., Creasy, C.L., Peterson, J., and Chernoff, J. The tumor suppressor Mst1 promotes changes in the cellular redox state by phosphorylating and inactivating peroxiredoxin-1. J. Biol. Chem. 288:8762-71, 2013.
103. Arias-Romero, L. E., Villamar-Cruz, O., Huang, M., Hoeflich, K.P., and Chernoff, J. p21activated kinase-1 links ErbB2 to β-catenin in transformation of breast epithelial cells. Cancer Res., 73:3671-82, 2013.
104. Aslan, J., Itakura, A., Haley, K., Tormoen, G., Loren, C., Baker, S., Pang, J., Chernoff, J., and McCarty, O.J.T. PAK signaling coordinates GPVI-mediated platelet aggregation, lamellipodia formation and aggregate stability under shear. Arterioscler. Throm. Vasc. Biol. 33:1544-51, 2013.
105. Aslan, J.E., Baker, S.M., Loren, C.P., Haley, K.M., Itakura, A., Pang, J., Greenberg, D.L., David, L.L., Chernoff, J., Manser, E., and McCarty, O.J.T. The PAK system links Rho GTPase signaling to thrombin-mediated platelet activation. Am. J. Physiol. Cell Physiol. 305:C519-28, 2013.
106. Radu, M., Rawat, S.J., Beeser, A. and Chernoff, J. ArhGAP15, a Rac-specific GTPase Activating Protein, plays a dual role in inhibiting small GTPase signaling. J. Biol. Chem. 288:21117-25. 2013.
107. Itakura A., Aslan, J.E., Kusanto, B.T., Phillips, K.G., Porter, J.E., Newton, P.K., Nan, X., Insall, R.H, Chernoff, J., and McCarty O.J. p21-activated kinase (PAK) regulates cytoskeletal reorganization and directional migration in human neutrophils. PLoS One 8:e73063, 2013.
108. Licciulli, S., Maksimoska, J., Zhou, C., Troutman, S., Kota, S., Lin, Q., Duron, S., Campbell, D., Chernoff, J., Field, J., Mamorstein, R., and Kissil, J.L. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of NF2-associated schwannomas. J. Biol. Chem. 288:29105-14, 2013.
109. Chiang, Y.A., Ip, W., Shao, W., Song, Z.E., Chernoff, J., and Jin, T. Activation of GLP-1 signaling attenuates impaired hepatic glucose disposal in aged male p21-activated protein kinase-1 knockout mice. Endocrinology 155:2122-32, 2014.
110. Kelly, M.L., Astsaturov, A., Rhodes, J., and Chernoff, J. A Pak1/Erk signaling circuit acts through Gata6 to regulate cardiovascular development in zebrafish. Dev. Cell 29:350-9, 2014.
111. Phee, H., Au-Yeung, B.B., Pryshchep, O., O’Hagan, K.L., Fairbairn, S.G., Radu, M., Kosoff, R., Mollenauer, M., Cheng, D., Chernoff, J., and Weiss, A. Pak2 is required for actin cytoskeleton remodeling, TCR signaling, and normal thymocyte development and maturation. Elife 3:e02270, 2014.
112. Elsherif, L., Ozler, M., Zayed, M.A., Shen, J.H., Chernoff, J., Faber, J.E., and Parise, L.V. Potential compensation among group I PAK members in hindlimb ischemia and wound healing. PLoS One 9:e112239, 2014.
113. Badolia, R., Manne, B.K., Dangelmaier, C., Chernoff, J., and Kunapuli, S.P. Gq-mediated Akt translocation to the membrane: a novel PIP3-independent mechanism in platelets. Blood 125:175-84, 2015.
114. Zeng, Y., Broxmeyer, H.E., Staser, K., Chitteti, B.R., Park, S.J., Hahn, S., Cooper, S., Sun,
Z., Jiang, L., Yang, X., Yuan, J., Kosoff, R., Sandusky, G., Srour E.F., Chernoff J., and Clapp D.W. Pak2 regulates hematopoietic progenitor cell proliferation, survival and differentiation. Stem Cells 33:1630-41, 2015.
115. Chow, H.Y., Dong, B., Duron, S.G., Campbell, D., Ong, C.C., Hoeflich, K.P., Chang, L.S., Welling, D.B., Yang, Z.j., and Chernoff, J. Group I Paks as therapeutic targets in NF2deficient meningioma. Oncotarget 10:1981-1994, 2015.
116. Ong, C.C., Gierke, S., Pitt, C., Sagolla, M., Cheng, C.K., Zhou, W., Jubb, A.M., Strickland,
L., Schmidt, M., Duron, S.G., Campbell, D.A., Zheng, W., Dehdashti, S., Shen, M., Yang,
N., Behnke, M.L., Huang, W., McKew, J.C., Chernoff, J., Forrest, W., Haverty, P.M., Chin, S.-F., Rakha, E.A., Green, A.R., Ellis, I.O., Caldas, C., O’Brien, T., Friedman, L.S., Koeppen, H., Rudolph, J., and Hoeflich, K.P. Small molecule inhibition of group I PAKs in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Res. 17:59, 2015.
117. Singh, N. K., Kotla, S., Dyukova, E., Traylor, J.G. Jr. Orr, A.W., Chernoff, J. Marion, T.N., Rao, G.N. Disruption of p21-activated kinase 1 gene diminishes atherosclerosis in apolipoprotein E-deficient mice. Nat. Comm. 6:7450, 2015.
118. O’Hagan, K.L., Choi, J., Pryshchep, O., Chernoff, J., and Phee, H. Pak2 Links TCR Signaling Strength to the Development of Regulatory T Cells and Maintains Peripheral Tolerance, J. Immunol. 195:1564-1577, 2015.
119. Kosoff„ R.E., Aslan, J.E., Kostyak, J.C., Dulaimi, E., Chow, H.-Y., Prudnikova, T.Y., Radu, M., Kunapuli, S.P., McCarty, O.J.T., and Chernoff, J. Pak2 restrains endomitosis during megakaryopoiesis. Blood 125:2995-3005, 2015.
120. Pandolfi, A., Stanley, R.F., Bartholdy, B., Pendurti, G., Gritsman, K., Boultwood, J., Chernoff, JH., Verma, A., and Steidl, U. PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood 126:1118-1127, 2015.
121. Radu, M., Lyle, K., Hoeflich, K.P., Villamar-Cruz, O., Koeppen, H., and Chernoff, J. p21activated kinase 2 (Pak2) regulates endothelial development and function through Bmk1/Erk5 pathway. Mol. Cell. Biol. 35:3990-2005, 2015 (cover story).
122. Prudnikova, T,Y., Villamar-Cruz, O., Rawat, S.J., Cai, K.Q., and Chernoff J. Effects of p21activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells. Oncogene 35:21782185, 2016.
123. Reddy, P.N.G., Radu, M., Xu, K., Wood, J., Harris, C.E., Chernoff, J., and Williams, D.A.
p21 activated kinase 2 regulates HSC cytoskeleton, migration and homing via CDC42 activation and interaction with b-Pix. Blood, 127:1967-1975, 2016.
124. Rawat, S.J., Araiza-Olivera, D., Arias-Romero, L.E., Villamar-Cruz, O., Prudnikova, T.Y., Roder, H., and Chernoff, J. H-ras inhibits the hippo pathway by promoting Mst1/Mst2 heterodimerization. Curr. Biol. 26:1556–1563, 2016. (Featured as “Editor’s Choice,” Sci.
Signaling 9:ec154, 2016; Recommended at F1000 Prime (http://f1000.com/prime/726388214).
125. Kurimchak, A.M., Shelton, C., Duncan, K.E., Johnson, K., Brown, J., Shane O’Brien, S., Gabbasov, R., Fink, L., Li, Y.S., Childers, W.E., Connolly, D.C., Chernoff, J., Peterson, J.R.
and Duncan, J.S. Adaptation of the kinome promotes resistance to BET bromodomain inhibitors in ovarian cancer. Cell Rep. 16:1273-1286, 2016 (Featured as “Research Highlight,” Nature Rev. Clin. Oncol. 19 Aug 2016; doi:10.1038/nrclinonc.2016.130).
126. Hu, B., Arpag, S., Zhang, X., Mobius, W., Werner, H., Sosinsky, G., Ellisman, M., Zhang, Y., Hamilton, A., Chernoff, J., and Li, J. Tuning PAK Activity to Rescue Abnormal Myelin Permeability in HNPP. PLoS Genet. 12:e1006290, 2016.
127. Villamar-Cruz, O., Prudnikova, T., Araiza-Olivera, D., Pérez-Plasencia, C., Johnson, N.,
Bernhardy, A., Slifker, M., Renner, C., Chernoff, J., and Arias-Romero, L. Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition, Oncotarget 7:76590-76603, 2016.
128. Prudnikova, T. and Chernoff, J. The Group I Pak inhibitor Frax-1036 sensitizes 11q13amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases, 8:193198, 2017.
129. Joseph, G.A., Lu, M., Radu, M., Lee, J., Burden, S.J., Chernoff, J., and Krauss, R.S. Group I Paks promote skeletal myoblast differentiation in vivo and in vitro. Mol. Cell. Biol. 37: e00222-16, 2017.
130. Semenova, G., Stepanova, D., Deyev, S.M., and Chernoff, J. Medium throughput biochemical compound screening identified novel agents for pharmacotherapy of neurofibromatosis type I. Biochimie 135:1-5, 2017.
131. Semenova, G., Stepanova, D., Dubyk, C., Handorf, E., Deyev, S.M., Lazar, A.J., and Chernoff, J. Targeting Group I p21-activated kinases to control tumor growth and metastasis in malignant peripheral nerve sheath tumors. Oncogene 36:5421-5431, 2017.
132. Stepanova, D.S., Semenova, G., Kuo, Y.-M., Andrews, A.J., Ammoun, S., Hanemann, C.O., and Chernoff, J. A novel function of the tumor suppressor gene NF2: Merlin controls fatty acid synthesis levels. Cancer Res. 77:5026-5038, 2017.
133. Tan, Y., Sementino, E., Chernoff, J., and Testa, J.R. Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity. Am. J. Cancer Res. 7:17241737, 2017.
134. Lu, H., Liu, S., Zhang, G., Wu, B., Zhu, Y., Frederick, D.T., Hu, Y., Zhong, W., Randell, S., Sadek, N., Zhang, W., Chen, G., Cheng, C., Zeng, J., Wu, L.W., Zhang, J., Liu, X., Xu, W.,
Krepler, C., Sproesser, K., Xiao, M., Miao, B., Liu, J., Song, C.D., Liu, J.Y., Karakousis,
G.C., Schuchter, L.M., Lu, Y., Mills, G., Cong, Y., Chernoff, J., Guo, J., Boland, G.M.,
Sullivan, R.J., Wei, Z., Field, J., Amaravadi, R.K., Flaherty, K.T., Herlyn, M., Xu, X., and Guo, W. PAK signaling drives acquired drug resistance to MAPK inhibitors in BRAF mutant melanomas. Nature 550:133-136, 2017. (N.B., author correction published Nature, 2019, 565(7738):E4. doi: 10.1038/s41586-018-0814-7)
135. Zeng, K., Tian, L., Sirek, A., Shao, W., Liu, L., Chiang, Y.T., Chernoff, J., Ng, D.S., Weng, J., and Jin, T. Pak1 mediates the stimulatory effect of insulin and curcumin on hepatic ChREBP expression. J. Mol. Cell Biol. 9:384-394, 2017.
136. Zeng, Y., Hahn, S., Stokes, J.L., Hoffman, E.A., Chernoff, J., and Katsanis, E. Pak2 regulates myeloid derived suppressor cell development in mice. Blood Adv. 1:1923-1933, 2017.
137. Araiza-Olivera, D., Feng, Y., Semenova, G., Prudnikova, T., Rhodes, J., and Chernoff, J. Suppression of RAC1-driven malignant melanoma by Group A PAK inhibitors. Oncogene 37:944-952, 2018.
138. Kim, S., Ravi, A., Nguyen, T., Kubiniok, P., Finicle, B., Malacrida, L., Hou, J., Jayashankar, V., Robertson, J., Chernoff, J., Digman, M., Potma, E., Tromberg, B., Thibault, P., and Edinger, A. PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells. Cancer Discovery 8:866-883, 2018.
139. Chow, H.Y., Dong, B., Valencia, C.A., Zeng, C.T., Koch, J.N., Prudnikova, T.Y. and Chernoff, J. Group I Paks are essential for epithelial-mesenchymal transition in an Apc driven model of colorectal cancer. Nature Comm. 9:3437, 2018.
140. Karchugina, S. and Chernoff, J. Detection of heterodimerization of protein isoforms using an in situ proximity ligation assay. J. Vis. Exp. doi:10.3791/57755, 2018.
141. Binder, P., Wang, S., Radu, M., Zin, M., Collins, L., Khan, S., Li, Y., Sekeres, K., Humphreys, N., Swanton, E., Reid, A., Pu, F., Oceandy, D., Guan, K., Hille, S.S., Frey, N., Müller, O.J., Cartwright, E.J., Chernoff, J., Wang., X., and Liu, W. Pak2 as a novel therapeutic target for cardioprotective endoplasmic reticulum stress response. Circ. Res. 124:696-711, 2019.
142. Korobeynikov, V., Borakove, M., Feng, Y., Wuest, W.M., Koval, A., Nikonova, A.N., Serebriiskii, I., Chernoff, J., Borges, V.F., Golemis, E.A., and Shagisultanova, E. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer. Breast Cancer Res. Treat. 177:369-382, 2019.
143. Kurimchak, A., Shelton, C., Duncan, K., Chernoff, J., Herrera-Montávez, and Duncan J. Intrinsic Resistance to MEK Inhibition Through BET protein mediated kinome reprogramming in NF1-deficient ovarian cancer. Mol. Cancer Res. 17:1721-1734, 2019.
144. Shen, Y.C., Arellano-Garcia, C., Menjivar, R., Jewett, E.M., Dohle, W., Karchugina, S., Chernoff, J., Potter, B.V.L., and Barald, K.F. Nonsteroidal sulfamate derivatives as new therapeutic approaches for Neurofibromatosis 2 (NF2). BMC Pharmacol. Toxicol. 20:67, 2019.
145. Sannai, M., Doneddu, V., Giri, V., Seeholzer, S., Nicolas, E., Yip, S.-C., Mancuso, P., Bassi, M., Cortellino, S., Cigliano, A., Lurie, R., Ding, H., Chernoff, J., Sobol, R., Yen, T., Bagella, L., and Bellacosa, A. Modification of the base excision repair enzyme MBD4 by the small ubiquitin-like molecule SUMO1. DNA Repair 82:102687, 2019.
146. Uribe-Alvarez, C., Guerrero-Rodríguez, S.L., Rhodes, J., Cannon, A., Chernoff*, J., and Araiza-Olivera*, D. Targeting effector pathways in RAC1P29S-driven malignant melanoma. Small GTPases 17:1-9, 2020. *co-corresponding authors
147. Kurimchak, A. M., Herrera-Montavez, C., Brown, J., Johnson, K.J., Sodi, V., Srivastava,
N., Kumar, V., Deihimi, S., O’Brien, S., Peri, S., Mantia-Smaldone, G.M., Jain, A., Winters, R.M., Cai, Q., Chernoff, J., Connolly, D.C., and Duncan, J.S. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma Sci. Signal. 13: eaax8238, 2020.
148. Hawley, E.T., Gehlhausen, J.R., Karchugina, S., Chow, H.-Y., Araiza-Olivera, D., Radu, M., Smith, A.B., Burks, C.A., Jang, L., Li, X., Masters, A.R., Edwards, D., Burgin, C., Jones, D., Bessler, W.K., Yates, C.W., Clapp, D.W*., Chernoff*, J., and Su-Jung, P. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2). Hum. Mol. Genetics 30:1607-1617, 2021. *co-corresponding authors.
149. Uribe-Alvarez, C., Lam, Q., Baldwin, D.A. and Chernoff, J. Low saliva pH can yield false Positive Result In simple RT-LAMP-based Sars-Cov-2 diagnostic tests. PLoS One 16:e0250202, 2021.
150. Kaur, N., Ruiz-Velasco, A., Raja, R., Howell, G., Miller, J.M., Riham R. E. Abouleisa, R.E., Ou, Q., Mace, K., Hille, S.S., Frey, N., Binder, P., Smith, C.P., Fachim, H., Soran, H., Swanton, E., Mohamed, T.M.A., Müller, O.J., Wang, X., Chernoff, J., Cartwright, E.J., and Liu, W. Paracrine signal emanating from stressed cardiomyocytes aggravates inflammatory microenvironment in diabetic cardiomyopathy. iScience 25:103973, 2022.
151. Binder, P., Nguyen, B., Collins, L., Zi, M., Liu, W., Christou, F., Luo, X., Hille, S.S., Frey, N., Cartwright, E.J., Chernoff, J., Müller, O.J., Guan, K., and Wang, X. Pak2 regulation of Nrf2 serves as a novel signalling nexus linking ER stress response and 1 oxidative stress in the heart. Frontiers Cardiovascular Med. 9:851419, 2022.
152. Sementino, E., Kadariya, Y., Cheung, M., Menges, C., Tan, Y.F., Kukuyan, A.-M., Shrestha, U., Karchugina, S., Cai, K., Peri, S., Duncan, J., Chernoff, J., and Testa, J.R. Inactivation of p21-activated kinase 2 inhibits development of Nf2-deficient Tumors by restricting hedgehog and Wnt signaling. Mol. Cancer Res. 20:699, 2022.
153. Kathania, M., Kumar, R., Lenou, E., Basrur, V., Chernoff, J., Thiess, A.L., and Venuprasad, K. Pak2-mediated phosphorylation promotes RORgt ubiquitination and inhibits colonic inflammation. Cell Reports 40:111345, 2022.
154. Saldivar-Cerón, H.I., Villamar-Cruz, O. Wells, C.M., Chernoff, J., Patino-Lopez, G., Huerta-Yepez, S., Montecillo-Aguado, M., Rivera-Pazos, C.M., Loza-Mejía, M.A., Vivar-Sierra, A., Briseño-Díaz, P., Zentella-Dehesa, A., Leon-Del-Rio, A., López-Saavedra, A., Padierna-Mota, L., de Jesús Ibarra-Sánchez, M., Esparza-López, L., Hernandez Rivas, R., and Arias-Romero, L.E. p21-Activated kinase 1 promotes breast tumorigenesis via phosphorylation and activation of the calcium/calmodulin-dependent protein kinase II Pak1 activates CaMKII signaling in breast cancer Front. Cell Dev. Bio. 9:759259, 2022.
155. Chow, H.-Y., Karchugina, S, Groendyke, B., Toenjes, S, Hatcher, J., Donovan, K., Fischer, E., Abalakov, G., F, B., Dunbrack, R., Gray, N., and Chernoff, J. Development and utility of a PAK1-selective degrader. J. Med. Chem. 65:15627–15641, 2022.
156. Wang, Y., Risteski, P.,Yang. Y., Chen, H., Droby, G., Ariel, P., Walens, A., Troester, M., Herring, L., Chernoff, J., Tolić, I.M., Bowser1, J., and Vaziri, C. TRIM69-STK3 signaling axis regulates centrosome dynamics and cancer cell survival (submitted).
157. Hu, B., Moiseev, D., Schena, I., Chernoff, J., and Li, J. PAK2 is Necessary for Myelination in the Peripheral Nerve System (submitted).
CHAPTERS, EDITORIALS, AND REVIEWS:
1. Chernoff, J., Schievella, A.R., and Neel, B.G. Molecular cloning and expression of a major human protein tyrosine phosphatase. Adv. Protein Phosphatases 6:59-71, 1991.
2. Sells, M.A. and Chernoff, J. Polymerase chain reaction cloning of related genes. Meth. Enzymol. 254:184-195, 1995.
3. Sells, M.A. and Chernoff, J. Emerging from the Pak: the p21-activated protein kinase family. Trends Cell Biol. 7:162-167, 1997.
4. Chernoff, J. Protein tyrosine phosphatases as negative regulators of mitogenic signaling. J. Cell. Physiol. 180:173-181, 1999.
5. Chernoff, J. Close encounters of the LIM kinase. Nature Cell Biol. 1:E115-117, 1999.
6. Valster, A.H., Hepler, P.K., and Chernoff J. Plant GTPases: the Rhos in bloom. Trends Cell Biol, 10:141-146, 2000.
7. Chernoff, J. Mitogenic signal transduction, in Basic Science of Cancer, Current Medicine (Kruh, G.D and Tew, K.D., eds) 75-92, 2000.
8. Serebriiskii, I.G., Mitina, O.V., Chernoff, J., and Golemis, E.A. Use of a two-hybrid dual bait system to discriminate specificity of protein interactions in small GTPases. Meth. Enzymol. 332:277-300, 2001.
9. Cotteret, S. and Chernoff, J. The evolutionary history of effectors downstream of Cdc42 and Rac. Genome Biology 3: 0002.1-0002.8, 2002. (cover story)
10. Chernoff, J. Signal Transduction and Mammalian Cell Growth, in Protein-Protein Interactions: A Molecular Cloning Manual, CSHL Press (Golemis, E.A., ed) 7-13, 2002.
11. Jaffer, Z and Chernoff, J. p21-activated kinases: three more join the Pak. Int J. Biochem. & Cell Biol. 34:713-717, 2002.
12. Nikolic, M. and Chernoff, J. High midsummer for Rho GTPases. Trends Cell Biol. 12:495497, 2002.
13. Dadke, S. and Chernoff, J. Protein-Tyrosine Phosphatase 1B as a potential drug target for obesity. Curr. Drug Targets – Immune, Endocr. & Metabol. Disord. 3:243-248, 2003.
14. Beeser, A and Chernoff, J. Rho GTPases and Cell Motility, in Rho GTPases, Landes Biosciences publs (Symons, M., ed) 141-154, 2003. ISBN: 1-58706-199-6, epub http://eurekah.com/chapter.php?chapid=1384&bookid=104&catid=56.
15. Valster, A.H., Hepler, P.K., and Chernoff, J. Rho GTPases in plants, in Rho GTPases, Landes Biosciences publs (Symons, M., ed) 219-229, 2003. ISBN: 1-58706-199-6, epub http://www.eurekah.com/abstract.php?chapid=1333&bookid=104&catid=56.
16. Xiao, G.-H., Chernoff, J,. and Testa, J.R. NF2: The wizardry of Merlin. Genes Chrom. Cancer 38:389-399, 2003.
17. Jaffer, Z. and Chernoff, J. The cross Rho’ds of cell-cell adhesion. J. Biol. Chem.
279:35123-35126, 2004.
18. Hofmann, C., Shepelev, M., and Chernoff, J. The genetics of Pak. J. Cell. Sci. 117:43434354, 2004.
19. Sorokina, E. and Chernoff, J. Rho GTPases: new members, new pathways. J. Cell. Biochem. 94:225-231, 2005.
20. Golemis, E.A. and Chernoff, J. Editorial: Analysis and manipulation of intracellular signaling cascades. Methods, 32/4:347-348, 2005.
21. Chernoff J. STK4 (serine/threonine kinase 4). Atlas Genet. Cytogenet. Oncol. Haematol.
November 2005. URL:
http://AtlasGeneticsOncology.org/Genes/STK4ID42440ch20q11.html
22. Cotteret, S. and Chernoff, J. Pak GITs to Aurora A. Dev. Cell. 9:1–2, 2005.
23. Beeser, A and Chernoff, J. Production and use of a cell permeable inhibitor of group A Paks (TAT-PID) to analyze signal transduction. Methods 37:203-207, 2005.
24. Peterson, J.R. and Chernoff, J. Src transforms in a Cool way. Nat. Cell Biol. 8:905-907, 2006.
25. Chernoff, J. Pak5. UCSD-Nature Molecule Pages (2007). (doi:10.1038/mp.a000829.01).
26. Chernoff, J. PTP1B. UCSD-Nature Molecule Pages (2008). (doi:10.1038/mp.a000088.01).
27. Chernoff, J. Mst1. UCSD-Nature Molecule Pages (2008). (doi:10.1038/mp.a001348.01).
28. Chernoff, J. Mst2. UCSD-Nature Molecule Pages (2008). (doi:10.1038/mp.a001347.01).
29. Stepanova, D. and Chernoff J. PAK1 (p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast)). Atlas Genet Cytogenet Oncol Haematol. December 2007.
30. URL: http://AtlasGeneticsOncology.org/Genes/PAK1ID41633ch11q13.html
31. Arias-Romero L.E. and Chernoff, J. A tale of two Paks. Biology of the Cell 100:97-108, 2008.
32. Radu, M. and Chernoff, J. The deMSTification of Mammalian Sterile-20 Kinases. Curr. Biol. 19:R421-R425, 2009.
33. Pacheco, A. and Chernoff, J. Group I p21-Activated kinases: emerging roles in immune function and viral pathogenesis. Int J. Biochem. & Cell Biol. 42:13-16, 2010.
34. Van den Broeke, C., Radu, M., Chernoff, J., and Favoreel, H. An emerging role for p21activated kinases (Paks) in viral infections. Trends Cell Biol. 20:160-169, 2010.
35. Cerione, R., Chernoff, J., Kahn, R.A., Knaus, U. Gary M. Bokoch (1954–2010), Dev. Cell 18: 357-358, 2010.
36. Yip, S.C., Saha, S., and Chernoff, J. Protein Tyrosine Phosphatase 1B: a cellular double agent in metabolism and oncogenesis. Trends Biochem. 35:442-449, 2010.
37. Kosoff, R. and Chernoff, J. LOV conquers (sm)all GTPases. F1000 Biology Reports, 2:28 doi:10.3410/B2-28, 2010.
38. Arias-Romero, L. and Chernoff, J. p21-activated kinases in ErbB2-positive breast cancer: a new therapeutic target? Small GTPases 1:124-128, 2010.
39. Huson, S.M., Acosta, M.T., Belzberg, A., Bernards, A., Chernoff, J., Cichowski, K., Evans,
D.G., Ferner, R.E., Giovannini, M., Korf, B., Listernick, R., North, K., Packer, R., Parada, L.F., Peltonen, J., Ramesh, V., Reilly, K., Schorry, E., Uphadyaya, M., Viskochil, D., Zhu,
Y., Hunter-Schaedle, K., Giancotti, F. Conference Report: Back to the Future: Proceedings from the 2010 NF Conference. Am. J Med. Gen. 155:307-321, 2010.
40. Arias-Romero, L.E. and Chernoff J. p21-activated kinases in Erbb2-positive breast cancer: A new therapeutic target? Small GTPases 1:124-128, 2010.
41. Kelly, M.L. and Chernoff, J. Getting smart about p21-activated kinases. Mol. Cell Biol. 31:386-387, 2011.
42. Semenova, G. and Chernoff, J. PKM2 enters the morpheein academy. Mol. Cell. 45:583584, 2012.
43. Kelly, M.L. and Chernoff, J. Mouse models of Pak function. Cell Logist. 2:84-88, 2012.
44. Kelly, M.L., Astsaturov, A., and Chernoff, J. Role of p21-activated kinases in cardiovascular development and function. Cell Mol Life Sci 70:4223-4228, 2013.
45. Arias-Romero, L.E. and Chernoff, J. Targeting Cdc42 in cancer. Exp Op. Ther. Targ. 17:1263, 2013.
46. Hoeflich, K.P., Rudolph, J., Crawford, J., and Chernoff, J. Small molecule inhibitors of Pak. The Enzymes 34:157-180, 2013.
47. Saha, S. and Chernoff, J. Analysis of PTP1B sumoylation. Methods, 65:201-206, 2014.
48. Radu, M., Semenova, G., Kosoff, R., and Chernoff, J. PAK signalling during the development and progression of cancer. Nat. Rev. Cancer 14:13-25, 2014.
49. Baker, N.M., Yee Chow, H., Chernoff, J, and Der, C.J. Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers. Clin. Cancer Res. 20:4740-6. 2014.
50. Prudnikova, T.Y., Rawat, S.J., and Chernoff, J. Molecular pathways: targeting the kinase effectors of RHO-family GTPases. Clin. Cancer Res. 21:24-9, 2015.
51. Rawat, S.J. and Chernoff, J. Regulation of mammalian Ste20 (Mst) kinases. Trends Biochem. Sci. 40:149-56, 2015.
52. Wells, G., Chernoff, J., Gilligan J.P., and Krause, D.S. Does salmon calcitonin cause cancer: a review and meta-analysis. Osteoporos. Int. 27:13-9, 2016.
53. Chernoff, J. Rac1. Cancer Therapeutic Targets (Springer New York, J.L. Marshall ed.) 1-5, 2016, doi:10.1007/978-1-4614-6613-0_24-2.
54. Bellacosa, A., Chernoff, J., and Testa, J.R. Alfred G. Knudson (1922–2016), Cell 166: 785786, 2016.
55. Araiza-Olivera, D. and Chernoff, J. Hras helps Hippo heterodimerize to evade tumor suppression, Small GTPases, doi: 10.1080/21541248.2016.1228794, 2016.
56. Semenova, G. and Chernoff, J. Targeting PAK1. Biochem. Soc. Trans. 45:79-88, 2017.
57. Chernoff, J. Alfred G. Knudson: in Memorium (1922-2106). Cancer Res. 77:815-816, 2017.
58. Radu, M. and Chernoff, J. Recent advances in methods to assess the activity of the kinome. F1000Research, 6:1004, 2017.
59. Stepanova, D.S. and Chernoff, J. A new concept in NF2 pharmacotherapy: targeting fatty acid synthesis, Oncoscience 5:126-127, 2018.
60. Chernoff, J. How to get and keep your lab funded. Mol. Biol. Cell 29:2519-2521, 2018.
61. Chernoff, J. What is my paper really worth? Mol. Biol. Cell 30:2878-2879, 2019.
62. Benton, D. and Chernoff, J. A new Rho(d)-map to diffuse gastric cancer. Cancer Discov. 10:182-184, 2020.
63. Cannon, A., Uribe-Alvarez, C., and Chernoff, J. The emerging roles of Rac1 in cancer. Trends Cancer 6:478-488, 2020.
64. Budagyan, K. and Chernoff, J., Ras isoform signaling analysis. Methods Mol. Biol. (in press).
65. Chernoff, J. 2020 in 20/20 hindsight. Mol. Biol. Cell 32:1007-1008, 2021.
66. Karguchina, S., Benton, D., and Chernoff, J. Regulation of MST complexes and activity via SARAH domain modifications. Biochem. Soc. Trans. 49:675-683, 2021.
67. Chernoff, J. The two-hit theory hits fifty. Mol. Biol. Cell 32: 2021, https://doi.org/10.1091/mbc.E21-08-0407.
68. Chernoff, J. (Obituary) Beatrice Mintz, PhD, pioneering researcher at Fox Chase, dies at 100. The Cancer Letter 48, No. 01, January 07, 2022.
69. Skalka, A.M. and Chernoff, J. Beatrice Mintz: In Memoriam. Cancer Res. 82:739–740, 2022.
70. Chernoff, J. The Institutes for Cancer Research Murderer’s Row. The Cancer Letter 48, No. 20, May 20, 2022.
71. Chernoff, J. Getting back to where we once belonged. The Cancer Letter 48, No. 31, August 5, 2022.
72. Payaningal S.R., Chernoff, J., Cummings, B.S., Prasad, S.M., and Homan, H.D. Targeting p21-activated kinase-1 for metastatic prostate cancer. Cancers 15, 2236-, 2023.
EDITORIAL PROJECTS
Golemis E.A. and Chernoff, J. Editors, Analysis and Manipulation of Intracellular Signaling Cascades. Methods, 32/4:347-348.
POSTDOCTORAL TRAINING
Training Name Current Position
1992 - 1995 Caretha Creasy, PhD Oncology Early Development Leader, GSK
1993 - 1996 Diane Ambrose Clin. Res. Ctr. UMDNJ
1997 - 1998 Robert Louden Assoc. Teaching Professor, Dept. of Biology, Drexel University
1997 – 2002 Melissa Reeder Cell Pathways
1998 – 2005 Shrikrishna Dadke VP, Biopharma, Vimta Labs Ltd, Hyderabad, India
2001 – 2006 Alexander Beeser Asst. Prof. of Biology, Lyon College, Batesville, Arkansas
2002 – 2005 Elena Sorokina Sr. Research Scientist, Univ. of Pennsylvania
2000 – 2007 Zahara Jaffer Asst. Dir., Technology Licensing, U. Florida
2001 – 2007 Clemens Hofman Clinical Supply Chain Manager, Fisher Clinical Services, Freiburg, Germany
2001 – 2008 Sophie Cotteret Clinical cytogeneticist & molecular biologist, Institut de Cancérologie (GRCC), Villejuif, France
2008 – 2010 Almudena Pacheco Sr. Scientist, Summation Bio, Lab Central
2006 – 2011 Jenny Yip Director of Business Development, PhenoVista Biosciences
2006 – 2014 Luis Arias Romero Assoc. Prof., Nat’l Cancer Inst. Mexico
2008 – 2018 Hoi Yee (Betty) Chow Assoc. Prof., Sichuan University, China
2008 – 2018 Maria Radu Sr. Scientist, Merck
2008 – 2013 Sayanti Saha Director, Partnerships and Transformation, Horizon Blue Cross Blue Shield of New Jersey
2008 – 2010 Christine Lightcap Director, Integrated Product Development at PharmaLex
2012 – 2020 Tatiana Prudnikova Investigator, GlaxoSmithKline
2014 – 2016 Daniela Araiza Research Associate, Fox Chase Cancer Center
2022 – present “ Assistant Research Professor
2018 – 2022 Cristina Uribe-Alvarez Postdoctoral Associate
2022 – present “ Assistant Research Professor
2023 – present Ramil Khusnutdinov Postdoctoral Associate
GRADUATE STUDENT TRAINING
Period Name Current Position
1995 – 1999 Feng Liu Wyeth Pharmaceuticals
1999 – 2000 Olga Mitina University of Munich (Warmuth lab)
2003 – 2004 Mikhail Shepelev Engelhardt Institute, Moscow
2006 – 2013 Dina Stepanova Research Associate, Russian National Research Medical University, Moscow
2009 – 2016 Sonali Jalan Senior Scientist, Merck
2009 – 2014 Rachelle Kosoff Principal Scientist, Translational Development, Century Therapeutics, LLC
2010 – 2014 Mollie Kelly Editor, Life Sciences, Cactus Communications
2011 – 2018 Galina Semenova Postdoctoral Fellow, Fred Hutchinson Cancer Center
2018 – 2019 Cong Tao Zeng Student, Sichuan University, China
2017 – 2023 Sofiia Karchugina Graduate Student, RMSU, Chernoff Lab
2018 – 2023 Alexa Cannon Graduate Student, Drexel University, Chernoff Lab
2018 – 2023 Konstantin Budagyan Graduate Student, Drexel University, Chernoff Lab
2019 – present Dorothy Benton Graduate Student, Drexel University, Chernoff Lab
2019 – 2021 Gleb Abalakov Postdoctoral Fellow, Temple University
UNDERGRADUATE STUDENT TRAINEES
1-2 high school and/or college student per year since 1992
FCCC SERVICE
1994 – 1997 Postdoctoral committee
1997 – present Library committee
1997 – present Seminars for medical oncology fellows (1x/yr)
1997 – present Various promotion committees
1998 – present Program Leader, Cancer Biology
1998 – 2000 Assisted Dr. Erica Golemis with setting up FCCC/RSMU sister-institution program
2001 – 2002 Leap-frog lecture series
2001 – present FCCC/Ben Gurion University Program
2003 – present FCCC/Drexel liaison
2003 – 2004 Vice President’s Advisory Board, Basic Science
2006 – 2008 Appointments & Promotions
2007 – present ECOR Committee (Chair)
2009 – 2010 Search Committee (Chair), EPC Program
2010 Faculty Senate Organizing Committee
2010 – 2011 Co-Leader, EPC Keystone Program
2012 – 2014 Temple/FCCC Science Integration Committee (Co-chair)
2015 – present FCCC Internal Advisory Board
2013 – 2022 Nominations Committee (Chair)
TEACHING
1995 “Signal Transduction” (Postdoctoral course at FCCC)
1997, 1998 “Signaling to the Cytoskeleton” (Physiology Course, Marine Biology Lab, Woods Hole
2001 – 2005 “Protein-Tyrosine Phosphatases” University of Pennsylvania BMB-550
2005 – present “Protein Kinases” Drexel University SOM
2005 – present “Lipid Kinases and Rho Proteins” Drexel University SOM
2013 – 2014 “Protein Kinases” University of Pennsylvania BMB-633
GRANTS FUNDED
1978 - 1984 Medical Scientist Training Grant
1989 - 1991 PHS NRSA Postdoctoral Grant
1993 - 1998 NIH 1 R01 CA58836: “A Tumor Suppressing Protein Tyrosine Phosphatase”
1998 - 2003 NIH 1 R01 CA58836: “A Tumor Suppressing Protein Tyrosine Phosphatase”
2003 - 2008 NIH 1 R01 CA58836: “A Tumor Suppressing Protein Tyrosine Phosphatase”
1993 - 1996 Council for Tobacco Research, #3480: “Protein Tyrosine Phosphatase as Signal Transduction Probes”
1993 - 1996 W.W. Smith Foundation #C9201: “Protein Required for Transformation by the v-src Gene”
1996 - 1997 Institutional Pilot Project Grant: “Genetic strategies for Identifying Proteins Involved in Cell Polarity Control
1997 - 2001 NIH 1 R01 GM54168: “Regulation of p21-activated Kinases”
1997 - 2000 American Cancer Society, #CB-189: “Protein Kinases that Regulate Cell Shape and Polarity”
2000 - 2002 American Cancer Society, #CB-189: “Protein Kinases that Regulate Cell Shape and Polarity”
2002 - 2004 American Cancer Society, #CB-189: “Protein Kinases that Regulate Cell Shape and Polarity “
1997- 2002 Leukemia Society of America (Scholar): #1005-98
2004 - 2006 PA Tobacco Formula Grant: “Assessing HER-2 Targets in Breast Cancer”
2005 - 2007 DOD: NR050032: “Identification of Protein Kinases Required for NF2 Signaling”
2007 - 2008 CTF: 2007B-05-003 “Synthetic lethal screen of FDA-approved drugs in NF2”
2005 - 2009 DOD: NF050030: “Analysis of p21-Activated Kinase Function in Neurofibromatosis Type 2” - $1,200,000 direct costs
2008 - 2010 Seed Grant: FCCC “Identification of key signaling enzymes required for embryonic stem cell pluripotent” - $150,000 direct costs
2009 - 2010 CTF: 2009A-05-002: “Use of Induced Progenitor Stem Cells to Treat NF1” - $30,000 direct costs
2008 - 2011 American Asthma Foundation: “p21-Activated Kinase-1 as a Novel Therapeutic Target in Asthma” - $750,000 direct costs
2007 - 2012 NIH 1 R01CA117884-8: “Function of p21-activated Kinases” - $1,050,000 direct costs
2010 - 2012 DOD NF093118: “Role of p21-Activated Protein Kinases in Neurofibromatosis 2 - $174,500 total costs (H.Y Chow, postdoctoral fellowship)
2011 - 2012 SPORE pilot project: “p21-activted kinases as therapeutic targets in ovarian cancer - $50,000 total costs
2008 - 2012 BSF: 2007038 “Spatio-temporal regulation of p21-actiated kinases (Pak) in a T cell model system” - $180,000 direct costs
2010 - 2012 DOD NF093039: “Use of Induced Progenitor Stem Cells to Treat NF1” - $150,000 direct costs
2010 - 2013 DOD BC097800: “Role of PTP1B in HER2 Signaling in Breast Cancer” - $523,000 total costs (S. Saha, postdoctoral fellowship)
2011 - 2013 CTF Preclinical Consortium Center: “Preclinical drug testing in NF2” - $250,000 total costs
2014 - 2017 DOD NF130108: “Testing the Role of p21-Activated Kinases in Schwannoma Formation Using a Novel Genetically Engineered Murine Model that Closely Phenocopies Human NF2 Disease” - $575,000 direct costs
2016 - 2017 Breast Cancer Alliance Exceptional Project Grant: “Dissecting a Breast Cancer Amplicon using CRISPR/Cas” - $100,000 direct costs
2015 - 2018 ACS 122275-IRG-92-027-18-IRG: “Institutional Research Grant” - $180,000 direct costs
2015 - 2020 NIH 1 R01 CA142928: “p21-Activated Kinases as New Therapeutic Targets in Neurofibromatosis Type 1” - $1,125,000 direct costs
2016 - 2021 NIH 1 R01 CA148805: “The Role of p21-Activated Kinases in Malignant Mesothelioma” - $1,200,000 direct costs
2018 - 2023 NIH 1 R01 CA227184: “Targeting the Rac1 Signaling Pathway in Malignant Melanoma” - $1,250,000 direct costs
2018 - 2020 Melanoma Research Foundation: “RAC1 mutant melanoma: models and therapeutics” - $200,000 direct costs
2020 - 2023 NIH 1 R01 NS066927 (Jun Li, PI): “Pathophysiology of Conduction Blocks in HNPP” (subcontract from Vanderbilt) - $66,000 direct costs
2016 - 2021 NIH-T32-CA009035-41 (PI: Chernoff): “Training Program in Postdoctoral Research”
2016 - 2023 P30 CA006927 (PI: Fisher): “Comprehensive Cancer Center Program at Fox Chase”
2022 - 2023 PA Breast Cancer Alliance (PI: Chernoff): “Identifying and targeting key driver genes within a breast cancer amplicon” - $50,000 direct costs
2022 - 2023 Children’s Tumor Foundation (PI: Chernoff): “Evaluation of a PAK1-selective PROTAC, alone and with Hippo inhibitors, as a targeted therapy in NF2” - $40,000 direct costs
EDITORIAL REVIEW SERVICE
1999 - 2005 Journal of Biological Chemistry, Editorial Board
2008 - 2019 Molecular Biology of the Cell, Editorial Board
2015 - present Cancer Biological Therapy, Editorial Board
2020 - present Cancers
2021 - present Cancer Biology Section, Oncology Gateway, F1000 Research
2022 - present Aging and Cancer Research & Treatment
*Frequent reviewer: Nature Cell Biology, Science Signaling, Molecular Cell, Current Biology, Journal of Cell Biology, Molecular Cellular Biology, Oncogene, and PNAS
GRANT REVIEW SERVICE
1999 - 2000 Ad hoc reviewer for CDB-2 (now MBY-3)
1999 - 2000 ACS Cell Signaling and Metastasis
2002 DOD NF panel A
2005 The Leukemia and Lymphoma Society
1999 - 2002 Tobacco Related Disease Research Program, CA
2005 - 2007 Tobacco Related Disease Research Program, CA
2008- NIH R13 review panel
1998 & 2003 Program Project Grant - University of Virginia PPG “Signaling in time and Space”
2007 Program Project Grant - University of North Carolina PPG “Biosensors for Sensitive Multiplex Analysis of Endogenous Proteins”
2007 Program Project Grant - University of Wisconsin PPG “Low molecular weight GTPases in vascular biology”
2007 Children’s Tumor Foundation - Drug Discovery Initiative Award (Co-chair)
2008 – 2011 New Jersey Commission on Cancer Research
2009 – present AIRC - Italian Association for Cancer Research
2010 Member, College of CSR Reviewers
2010 – 2012 DOD NFRP Integration panel
2013 – present Fundación La Murato de TV3 (Spain)
2013 Austrian Science Fund
2013 – present La Caixa (Spain)
2013 CCSG site visits: Masonic CCC, JAXCC
2015 NIH Outstanding Investigators panel (R35)
2016 AACR Basic Cancer Research Fellowships Scientific Review Committee
2016 NIH Provocative Question (PQ6) panel
2018 CCSG site visit: Hollings CC (MUSC)
2018 NIDDK Board of Scientific Counselors Review
2019 AACR Outstanding Investigator Award for Breast Cancer Research Selection Committee
2020 Melanoma Research Foundation
2021 DOD Neurofibromatosis, CET-1 panel
2021 Chair, DOD Melanoma Research Program, CMB-2 panel
2022 Children’s Tumor Foundation - Drug Discovery Initiative Award
2022 Chair, DOD Neurofibromatosis, CET-1 panel
2022 FWO (Fonds voor Wetenschappelijk Onderzoek) Vlaanderen, Belgium
2022 Chair, DOD Melanoma Research Program, CMB-2 panel
2023 AACR Small Molecule Therapeutic Agents Section of the Experimental Therapeutics Subcommittee of the Program Committee
2023 CCSG Site visit: CINJ
EXTERNAL ADVISORY BOARDS
2004 - 2011 Scientific Advisory Board: Nexgenix Pharmaceuticals
2008 - 2013 Genentech
2008 - 2011 Novartis
2011 - 2016 NYU Cancer Institute EAB
2012 - 2014 Case Western Cancer Signaling Program EAB
2013 - 2017 Scientific Advisory Boards: Tarsa, Pharma-Arava, Enteris
2017 - present External Advisory Board: U. Miami Epigenetics T32
2019 - 2020 Novo-Nordisk
2019 - present Scientific Advisory Board: NF2 BioSolutions
2021 - present BloodQ
2022 - present Metastyx
INVITED SEMINARS
(unrecorded prior to 1996)
March 1996 Clinical Research Institute of Montreal, Canada
April 1996 Merck, West Point, PA
June 1996 University of Pennsylvania, Philadelphia, PA
October 1996 Harvard Medical School, Boston, MA
October 1996 Washington University, St Louis, MO
December 1996 University of Pennsylvania, Philadelphia, PA
May 1997 Cold Spring Harbor meeting on Tyrosine Phosphorylation - Invited Speaker
July 1997 Marine Biology Lab, Woods Hole, MA
July 1997 Astra Zeneca
October 1997 Wistar Institute, Philadelphia, PA
January 1998 Merck, West Point, PA
May 1998 Johns Hopkins Medical School, Baltimore, MD
June 1998 Massachusetts General Hospital Cancer Center, Boston, MA
July 1998 Marine Biology Lab, Woods Hole, MA
August 1998 Salk Institute meeting on Tyrosine Phosphorylation - Invited Speaker
October 1998 University of Massachusetts, Amherst (Invited by Graduate Students)
November 1998 Indiana University School of Medicine (Invited by Graduate Students)
November 1998 Medical Research Institute, Indianapolis, IN
December 1998 Albert Einstein College of Medicine, NY, NY
January 1999 Institute of Molecular Genetics, Prague, Czech Republic
February 1999 National Cancer Institute, Bethesda, MD
February 1999 Astra Zeneca
March 1999 FASEB: Small GTPases, Santé Fe, NM - Invited Speaker
April 1999 M.D. Anderson, Houston, TX
May 1999 Onyx Pharmaceuticals, CA
July 1999 Englehart Conference, Moscow, Russia. Invited Speaker
July 1999 FASEB: Protein Kinases and Phosphorylation, Snowmass CO - Invited Speaker
November 1999 Harvard Medical School, Boston, MA
February 2000 MCP Hahnemann, Philadelphia, PA
April 2000 The Picower Institute, NY
May 2000 Medical College of Wisconsin, Milwaukee, WI
May 2000 Onyx Pharmaceuticals, CA
May 2000 Netherlands Cancer Institute, Amsterdam, Netherlands
May 2000 Ludwig Institute for Cancer Research London, UK
May 2000 Aventis Pharmaceuticals, Munich, Germany
July 2000 FASEB: The Ras Superfamily of Small GTP-binding Proteins, Snowmass CO - Invited Speaker
March 2001 Albert Einstein College of Medicine, NY, NY
April 2001 Indiana University, Indianapolis, IN
April 2001 University of North Carolina, Chapel Hill NC
April 2001 Morphochem Inc., Princeton, NJ
May 2001 Sugen, Inc., S. San Francisco, CA
July 2001 Ben Gurion University, Beer Sheva, Israel
August 2001 Gordon Conference: Mechanisms of Cell Signalling, Oxford UK - Invited Speaker
August 2001 Karolinska Institute, Huddinge, Sweden
November 2001 University of North Carolina, Chapel Hill, NC
March 2002 Mount Sinai School of Medicine, NY, NY
April 2002 University Medical and Dental College of New Jersey, Newark, NJ
May 2002 University of California, Los Angeles, CA
July 2002 FASEB: Small G protein Networks in Cell Dynamics, Snowmass CO - Invited Speaker
October 2002 Stony Brook, NY
October 2002 Long Island Jewish Hospital, NY
October 2002 Cold Spring Harbor Laboratories, NY
June 2003 Gordon Conference: Mechanisms of Cell Signaling, Ventura, CA - Invited Speaker
September 2003 Mt. Sinai School of Medicine; MD. Ph.D. retreat
December 2003 University of Cincinnati, Cincinnati, OH
February 2004 Mt. Sinai School of Medicine; MD. Ph.D. dinner, NY, NY
April 2004 University of Florida, Tampa, FL
July 2004 FASEB: Small G Protein Networks in Cell Dynamics, Snowmass CO - Invited Speaker
November 2004 Columbia University, NY, NY
December 2004 Roswell Park Cancer Institute, Buffalo, NY
February 2005 University of Pennsylvania, Philadelphia, PA
April 2005 New York University, NY, NY
June 2005 Gordon Conference: Mechanisms of Cell Signaling, Hong Kong, China - Vice-Chair
September 2005 University of Oklahoma, Oklahoma City, OK
November 2005 Banbury Conference: Barriers & Solutions in the Use of Mouse Models to Develop Therapeutic Strategies for NF1 and NF2 - Associated Tumors - Invited Speaker
December 2005 Wayne State, Michigan, Detroit, MI
May 2006 University of California, Riverside, CA
May 2006 Scripps University, La Jolla, CA
May 2006 University of South Dakota, Sioux Falls, SD
May 2006 Wyeth Pharmaceuticals, Pearl River, NY
July 2006 FASEB: Small G Protein Networks in Cell Dynamics, Saxtons River VT - Vice-Chair
October 2006 University of Alberta, Edmonton, Canada
February 2007 Ben Gurion University, Beer-Sheva, Israel, Dozer Lecturer
February 2007 Tel Aviv University, Tel-Aviv, Israel
March 2007 University of Virginia, Charlottesville, VA
September 2007 Thomas Jefferson School of Medicine, Philadelphia, PA
September 2007 University of Gent, Gent, Belgium
September 2007 Gordon Conference: Mechanisms of Cell Signaling, Oxford, UK - Chair
September 2007 Oxford University, Oxford, UK
October 2007 Indiana University School of Medicine, Indianapolis, IN
November 2007 University of Illinois School of Medicine, Chicago, IL
April 2008 Genentech, San Francisco, CA
May 2008 Georgetown University, Washington, D.C.
May 2008 University of Cincinnati, Cincinnati, OH
June 2008 Weis Center for Research, Danville, PA
July 2008 FASEB: Regulation and Function of Small GTPases, Saxtons River VT - Invited Speaker
September 2008 New York University, NY, NY
October 2008 University of Pennsylvania, Philadelphia, PA
January 2009 Novartis, Emeryville, CA
August 2009 Gordon Conference: Mechanisms of Cell Signaling, Oxford, UK - Invited Speaker
October 2009 Kansas State University, Manhattan, KS
October 2009 Lankenau Institute for Medical Research
March 2010 Novartis, Emeryville, CA
March 2010 Genentech, San Francisco, CA
March 2010 Case Western, Cleveland, OH
May 2010 Mt Sinai School of Medicine, NY, NY
May 2010 University of Virginia, Charlottesville, VA
May 2010 American Asthma Foundation, San Francisco, CA
June 2010 Neurofibromatosis Conference, Baltimore, MD - Session Chair
June 2010 Russian Academy of Science conference: Control of Gene Expression, Moscow, Russia - Session Chair
July 2010 FASEB: Protein Kinases and Phosphorylation, Snowmass, CO - Invited Speaker
October 2010 University of West Virginia, Morgantown, WV
May 2011 Genentech, San Francisco, CA
June 2011 FASEB: Regulation and Function of Small GTPases, Saxtons River, VT - Invited Speaker
November 2011 Case Western, Cleveland, OH
February 2012 Commonwealth Medical College, Scranton, PA
March 2012 Memorial Sloan Kettering Cancer Center, NY, NY
May 2012 Genentech, San Francisco, CA
June 2012 Neurofibromatosis Conference, New Orleans, LA - Invited Speaker
June 2012 Rutgers University School of Medicine, Piscataway, NJ
July 2012 University of Utah, Provo, UT (two lectures)
September 2012 University of North Carolina, Chapel Hill, NC
September 2012 Duke University, Durham, NC
October 2012 Temple University, Philadelphia, PA
December 2012 McGill University, Montreal, Canada
January 2013 Astra-Zeneca, Boston, MA
March 2013 New York University, MD/PhD retreat, Stowe, VT - Keynote Speaker
June 2013 FASEB: Regulation and Function of Small GTPases, Snowmass, CO - Invited Speaker
July 2013 Albert Einstein Medical School, NY, NY
September 2013 National Cancer Institute of Mexico, Mexico City (two lectures) - Distinguished Speaker
November 2013 PDDI Annual Drug Discovery Awards, Doylestown, PA - Keynote Presentation
December 2013 Temple University, Sol Sherry Thrombosis Center, Philadelphia, PA
March 2014 Perlmutter Cancer Center, NYU, NY, NY
April 2014 AACR, San Diego, CA - Targeting Rho GTPases and Their Kinases Effectors - Educational Session Chair
May 2014 Ohio State Cancer Center, Columbus, OH
May 2014 University of Leuven, Leuven, Belgium
May 2014 Karolinska Institute, Huddinge, Sweden
June 2014 Neurofibromatosis Conference, Washington, DC - Invited Speaker
June 2014 Biomedicine Research unit (UBIMED), Mexico City, Mexico - Plenary Lecture
January 2015 Oregon Health & Science University, Portland, SC
April 2015 Temple University, Philadelphia, PA
June 2015 FASEB: Regulation and Function of Small GTPases, Palm Beach, FL - Invited Speaker
January 2016 Medical University of South Carolina, Charleston, SC
February 2016 Temple University School of Medicine, Administrative Forum, Philadelphia, PA
February 2016 Yale University School of Medicine, New Haven, CT
March 2016 Yale University School of Medicine, Grand Rounds, New Haven, CT
May 2016 University of North Carolina, Chapel Hill, NC
September 2016 Temple University School of Medicine, Translational Day Award Lecture
February 2017 University of Miami, Miami, FL
May 2017 Frederick National Laboratory for Cancer Research, Frederick, MD
May 2017 Puerto Rico INBRE and COBRE Scientific Symposium, San Juan, PR - Invited Speaker
June 2017 FASEB: Regulation and Function of Small GTPases, Palm Beach, FL - Invited Speaker; Session Chair
August 2017 Albert Einstein Medical School, NY, NY
November 2017 Sidney Kimmel Cancer Center, Thomas Jefferson, Grand Rounds, Philadelphia, PA
February 2018 RISE program seminar, University of Puerto Rico, San Juan, PR
April 2018 UBIMED, UNAM, Mexico City, Mexico
April 2018 Instituto deQuimica, UNAM, Mexico City, Mexico
July 2018 Biochemical Society: Small G proteins in cellular signaling and disease, Cambridge, UK - Invited Speaker
August 2018 Coriell Institute, Camden, NJ
September 2018 American Society for Biochemistry & Molecular Biology 2018, Frontiers in RAS Pathobiology and Drug Discovery Special Symposium, Stratton, VT - Invited Speaker
March 2019 UC Davis Cancer, Sacramento, CA
May 2019 Fundacion Ramon Areces: The RAS superfamily and related pathways in healthy and disease, Santander, Spain - Invited Speaker
June 2019 Simposium Avances Biomedicos en Cancer y Enfermedades Cronico Degenerativas XV ANIVERSARIO UNIDAD DE BIOMEDICINA Facultad de Estudios Superiores Iztacala, UNAM, Mexico City, Mexico - Invited Speaker
October 2019 1st Pak symposium, NY, NY - Keynote Speaker
November 2019 University of Pittsburgh, Pittsburgh, PA
January 2020 Sidney Kimmel Cancer Center, Annual Retreat, Philadelphia PA - Keynote Speaker
February 2021 Turning Point Therapeutics (via Zoom)
November 2021 Turning Point Therapeutics (via Zoom)
February 2022 MPM Capital (via Zoom)
April 2022 Panel Speaker, Children’s Tumor Foundation NF2/SWN Workshop (via Zoom)
June 2022 FASEB: Regulation and Function of Small GTPases, Saxtons River, Vermont - Invited Speaker
September 2022 Biochemical Society: Small G proteins in cellular signaling and disease, Liverpool, UK - Invited Speaker
November 2023 Mexican Society for Biochemistry: Signal Transduction, Ensenada Baja California - Keynote Speaker